SG11202104121QA - Methods for synthesis of radionuclide complex - Google Patents

Methods for synthesis of radionuclide complex

Info

Publication number
SG11202104121QA
SG11202104121QA SG11202104121QA SG11202104121QA SG11202104121QA SG 11202104121Q A SG11202104121Q A SG 11202104121QA SG 11202104121Q A SG11202104121Q A SG 11202104121QA SG 11202104121Q A SG11202104121Q A SG 11202104121QA SG 11202104121Q A SG11202104121Q A SG 11202104121QA
Authority
SG
Singapore
Prior art keywords
synthesis
methods
radionuclide complex
radionuclide
complex
Prior art date
Application number
SG11202104121QA
Other languages
English (en)
Inventor
Lorenza Fugazza
Palo Francesco De
Donato Barbato
Maurizio F Mariani
Giovanni Tesoriere
Clementina Brambati
Original Assignee
Advanced Accelerator Applications Italy Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications Italy Srl filed Critical Advanced Accelerator Applications Italy Srl
Publication of SG11202104121QA publication Critical patent/SG11202104121QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SG11202104121QA 2018-10-31 2018-10-31 Methods for synthesis of radionuclide complex SG11202104121QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2018/079909 WO2020088767A1 (en) 2018-10-31 2018-10-31 Methods for synthesis of radionuclide complex

Publications (1)

Publication Number Publication Date
SG11202104121QA true SG11202104121QA (en) 2021-05-28

Family

ID=64083105

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104121QA SG11202104121QA (en) 2018-10-31 2018-10-31 Methods for synthesis of radionuclide complex

Country Status (11)

Country Link
US (3) US20200131224A1 (zh)
EP (1) EP3873874A1 (zh)
JP (2) JP2022516814A (zh)
KR (1) KR20210086637A (zh)
CN (2) CN118436813A (zh)
AU (1) AU2018447938B2 (zh)
BR (1) BR112021007851A2 (zh)
CA (1) CA3159337A1 (zh)
IL (1) IL282701A (zh)
SG (1) SG11202104121QA (zh)
WO (2) WO2020088767A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
CN116528904A (zh) * 2020-08-27 2023-08-01 普罗博开发商业中心 放射性药物和方法
KR20230066382A (ko) 2020-09-03 2023-05-15 큐리엄 유에스 엘엘씨 64Cu-DOTATATE의 스케일 업을 위한 방사성표지 및 제형
CN114685608B (zh) * 2020-12-29 2023-10-20 北京大学深圳研究生院 含有三硫醚键的环肽化合物或其衍生物、其合成方法和应用
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
IT202100024377A1 (it) * 2021-09-22 2023-03-22 Scogif S R L Apparecchio automatico per la sintesi di radiofarmaci a base peptidica ad uso diagnostico e/o terapeutico
IL313964A (en) * 2022-02-04 2024-08-01 Advanced Accelerator Applications METHODS FOR THE LARGE-SCALE SYNTHESIS OF RADIONUCLIDE COMPLEXES
US12090215B2 (en) * 2022-02-04 2024-09-17 Westinghouse Electric Company Llc Method and device for direct production of radio-isotope based cancer treatment pharmaceuticals

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101855509B1 (ko) * 2015-11-12 2018-05-09 한국원자력연구원 방사성 의약품의 제조를 위한 바이알 키트 및 이를 이용한 방사성 의약품의 제조 방법
US10596276B2 (en) * 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596278B2 (en) * 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Also Published As

Publication number Publication date
US20220041649A1 (en) 2022-02-10
CN112969675A (zh) 2021-06-15
AU2018447938B2 (en) 2024-06-13
US20210316019A1 (en) 2021-10-14
WO2020088767A1 (en) 2020-05-07
AU2018447938A1 (en) 2021-05-13
CA3159337A1 (en) 2020-05-07
CN118436813A (zh) 2024-08-06
US20200131224A1 (en) 2020-04-30
IL282701A (en) 2021-06-30
EP3873874A1 (en) 2021-09-08
JP2023178388A (ja) 2023-12-14
JP2022516814A (ja) 2022-03-02
WO2020089379A1 (en) 2020-05-07
KR20210086637A (ko) 2021-07-08
BR112021007851A2 (pt) 2021-08-03

Similar Documents

Publication Publication Date Title
IL282701A (en) Methods for the synthesis of a radionuclide complex
IL292754A (en) method of synthesis
IL255817B (en) Synthesis of heterocyclic compounds
IL262659B (en) Synthesis of indazoles
SG10202111790YA (en) Synthesis of omecamtiv mecarbil
IL262413B (en) Synthesis of indazoles
GB201801768D0 (en) Synthesis method
PT3611171T (pt) Método para a síntese de eliglustato e dos seus compostos intermédios
EP3845523C0 (en) PROCESS FOR SYNTHESIS OF CARIPRAZINE
HK1250719A1 (zh) 脫氧糖胺的合成
GB201701396D0 (en) Novel alternating-phase synthesis method
GB201710241D0 (en) New route of synthesis for opicapone
PT3368513T (pt) Processo para a síntese de pirfenidona
SG11202011378WA (en) Synthesis of tipifarnib
PT3759082T (pt) Processo para a síntese de 6-clorometiluracilo
EP3792296C0 (en) PROCESS FOR THE SYNTHESIS OF POLYETHERS
GB201903055D0 (en) Method of oligonucleaotide synthesis
GB201804905D0 (en) Cataltic synthesis of biarylic compounds
GB201805283D0 (en) Method of synthesizing a radiopharmaceutical
GB201807468D0 (en) Methods of synthesis
GB201917499D0 (en) Methods of synthesis
GB201809404D0 (en) Method of synthesis
GB201820685D0 (en) Synthesis of 8-chloroadenosine derivatives
PT3713939T (pt) Processo melhorado para a síntese de fármaco ligante vcseco- duba
GB201523222D0 (en) Levosimendan medicine intermediate for acetaminophen acetone synthesis method